Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS)

Q: What does CUSIP 482929106 represent in this 13F holders report?

CUSIP 482929106 is the security identifier for KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share in Q2 2025?

29 institutional investors reported KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 482929106

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 22,927,577
Total 13F shares: 13,362,268
Share change: -512,096
Total reported value: $35,677,274
Price per share: $2.67
Number of holders: 29
Value change: -$2,639,077
Number of buys: 11
Number of sells: 12

Quarterly Holders Quick Answers

What is CUSIP 482929106?
CUSIP 482929106 identifies KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 482929106:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Top shareholders of KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Samsara BioCapital GP, LLC	3/4/5	10%+ Owner	— class O/S missing	11,448,081	$115,348,575	—	18 Mar 2025	3/4/5
Samsara BioCapital, LLC	13F	Company	50%	11,448,081	$91,928,090	—	31 Mar 2025	13F
Morana Jovan-Embiricos	3/4/5	Director	— mixed-class rows	26,621,054 mixed-class rows	$21,077,598	—	10 Apr 2025	3/4/5
David Hallal	3/4/5	Director	— mixed-class rows	19,695,546 mixed-class rows	$15,590,520	—	10 Apr 2025	3/4/5
Ansbert Gadicke	3/4/5	Director, 10%+ Owner	— class O/S missing	16,704,963	$11,205,689	—	28 Jul 2022	3/4/5
ElevateBio, LLC	3/4/5	Director, 10%+ Owner	— class O/S missing	16,674,766	$11,185,433	—	28 Jul 2022	3/4/5
GILEAD SCIENCES, INC.	3/4/5 13D/G 13F	10%+ Owner · Company	3.9% from 13D/G	16,635,286	$11,158,950	—	27 Jun 2023	3/4/5 13D/G 13F
Vikas Sinha	3/4/5	Officer Title: President, Chief Financial Officer and Chief Executive Officer, Director, 10%+ Owner	— class O/S missing	774,118	$7,799,858	—	21 Feb 2025	3/4/5
F2 MG Ltd	3/4/5	Director, 10%+ Owner	— class O/S missing	9,828,091	$6,592,683	—	28 Jul 2022	3/4/5
Napoleone Ferrara	3/4/5	Director	— mixed-class rows	522,000 mixed-class rows	$5,078,203	—	10 Apr 2025	3/4/5
Octagon Capital Advisors LP	13F	Company	2.1%	481,000	$3,862,430	—	31 Mar 2025	13F
Samir Chandrakant Patel	3/4/5	Director	— mixed-class rows	370,800 mixed-class rows	$3,554,743	—	10 Apr 2025	3/4/5
TANG CAPITAL MANAGEMENT LLC	13F	Company	1.3%	309,221	$2,483,044	—	31 Mar 2025	13F
Siren, L.L.C.	13F	Individual	1.2%	282,586	$2,269,166	—	31 Mar 2025	13F
John R. Wilson	3/4/5	Director	— mixed-class rows	3,187,454 mixed-class rows	$2,123,051	—	25 May 2021	3/4/5
Juan Vera	3/4/5	Director	— class O/S missing	2,409,928	$1,909,386	—	06 Jun 2024	3/4/5
EcoR1 Capital, LLC	13F 13D/G	Company	1.1% from 13D/G	201,718	$1,619,796	—	31 Mar 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	0.5%	115,086	$924,141	—	31 Mar 2025	13F
Invus Global Management, LLC	13D/G	Invus Public Equities, L.P.	1.5%	282,586	$754,533	$0	30 Jun 2025	13D/G
Redmile Group, LLC	13F	Company	0.36%	82,955	$666,129	—	31 Mar 2025	13F
Diana Brainard	3/4/5	Chief Executive Officer, Director	— class O/S missing	723,363	$396,765	—	19 Nov 2024	3/4/5
Agustin Melian	3/4/5	Chief Medical Officer	— class O/S missing	453,529	$304,227	—	04 Oct 2021	3/4/5
Jeroen B. van Beek	3/4/5	Chief Commercial Officer	— class O/S missing	333,726	$223,863	—	16 Nov 2022	3/4/5
BlackRock, Inc.	13F	Company	0.12%	27,514	$220,938	—	31 Mar 2025	13F
Edward Miller	3/4/5	General Counsel	— class O/S missing	21,575	$217,385	—	21 Feb 2025	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.12%	26,787	$215,166	—	31 Mar 2025	13F
Malcolm Brenner	3/4/5	Director	— class O/S missing	263,929	$209,111	—	06 Jun 2024	3/4/5
TWO SIGMA ADVISERS, LP	13F	Company	0.09%	21,581	$173,295	—	31 Mar 2025	13F
Woodline Partners LP	13F	Company	0.09%	21,519	$172,798	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.08%	19,251	$154,586	—	31 Mar 2025	13F
RBF Capital, LLC	13F	Company	0.08%	17,391	$139,650	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.07%	16,582	$133,153	—	31 Mar 2025	13F
Squarepoint Ops LLC	13F	Company	0.06%	14,587	$117,134	—	31 Mar 2025	13F
MARSHALL WACE, LLP	13F	Company	0.06%	14,115	$113,343	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.06%	13,796	$110,782	—	31 Mar 2025	13F
Cintia Piccina	3/4/5	Chief Commercial Officer	— mixed-class rows	420,000 mixed-class rows	$98,608	—	03 Jul 2023	3/4/5
Ercem Atillasoy	3/4/5	Officer	— class O/S missing	131,372	$88,124	—	20 Oct 2022	3/4/5
Jeffrey S. Bornstein	3/4/5	Director	— class O/S missing	110,197	$87,309	—	06 Jun 2024	3/4/5
STATE STREET CORP	13F	Company	0.05%	10,710	$86,001	—	31 Mar 2025	13F
Ann M. Leen	3/4/5	Chief Scientific Officer	— mixed-class rows	597,600 mixed-class rows	$83,183	—	16 Aug 2022	3/4/5
UBS Group AG	13F	Company	0.04%	9,261	$74,366	—	31 Mar 2025	13F
FMR LLC	13F	Company	0.03%	7,806	$62,682	—	31 Mar 2025	13F
Derek N. Adams	3/4/5	Director	— class O/S missing	70,000	$55,461	—	06 Jun 2024	3/4/5
Shawn Tomasello	3/4/5	Director	— class O/S missing	70,000	$55,461	—	06 Jun 2024	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.02%	5,424	$43,555	—	31 Mar 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	1,434	$11,515	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.01%	1,296	$10,406	—	31 Mar 2025	13F
FEDERATED HERMES, INC.	13F	Company	0%	634	$5,091	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	295	$2,368	—	31 Mar 2025	13F
COLDSTREAM CAPITAL MANAGEMENT INC	13F	Company	0%	208	$1,671	—	31 Mar 2025	13F

Institutional Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) as of Q2 2025

As of 30 Jun 2025, Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) was held by 29 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 13,362,268 shares. The largest 10 holders included SAMSARA BIOCAPITAL, LLC, TANG CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, GILEAD SCIENCES, INC., Siren, L.L.C., VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, Redmile Group, LLC, Squarepoint Ops LLC, and MILLENNIUM MANAGEMENT LLC. This page lists 29 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

-2

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.